Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
药物研究
动物造模剂
/
动物造模剂
小分子阳性药 免疫与炎症疾病模型 泌尿系统疾病模型
/
神经系统模型
其他造模剂 抗类风湿关节炎 膀胱炎模型 其他泌尿疾病模型 心肌炎模型 炎症模型
/ Cyclophosphamide hydrate

环磷氮芥 /Cyclophosphamide hydrate {[allProObj[0].p_purity_real_show]}

货号：A143958 同义名： 环磷酰胺水合物;环磷酰胺一水物 / Cyclophosphamide monohydrate;Cyclophosphamide (hydrate)

Cyclophosphamide is a nitrogen mustard alkylating agent used in the treatment of cancers and autoimmune disorders.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Cyclophosphamide hydrate 化学结构 CAS号：6055-19-2
Cyclophosphamide hydrate 化学结构
CAS号：6055-19-2
Cyclophosphamide hydrate 3D分子结构
CAS号：6055-19-2
Cyclophosphamide hydrate 化学结构 CAS号：6055-19-2
Cyclophosphamide hydrate 3D分子结构 CAS号：6055-19-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Cyclophosphamide hydrate 纯度/质量文件 产品仅供科研

货号：A143958 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >

Cyclophosphamide hydrate 生物活性

描述 Cyclophosphamide triggers outer membrane blebbing, DNA fragmentation (as evidenced by TUNEL staining that highlights free 3'-OH DNA ends), and initiates cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression is capable of completely inhibiting the activation of both initiator and effector caspases, such as caspase 3, in cells treated with activated Cyclophosphamide. However, while Bcl-2 blocks the cytotoxic effects of activated Cyclophosphamide, it does not impede its cytostatic effects[1]. Cyclophosphamide also shows reversible inhibition of AChE with an IC50 value of 511 μM[2].
体内研究

When administered intraperitoneally (2mg per mouse in 0.1 mL PBS, to C3H mice with SW1 tumors), it enhances the proportion of cells staining positive for CD3, CD4, or CD8 in both spleens and tumors[4].
体外研究

Cyclophosphamide triggers outer membrane blebbing, DNA fragmentation (as evidenced by TUNEL staining that highlights free 3'-OH DNA ends), and initiates cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression is capable of completely inhibiting the activation of both initiator and effector caspases, such as caspase 3, in cells treated with activated Cyclophosphamide. However, while Bcl-2 blocks the cytotoxic effects of activated Cyclophosphamide, it does not impede its cytostatic effects[1].

Cyclophosphamide also shows reversible inhibition of AChE with an IC50 value of 511 μM[2].

作用机制 Cyclophosphamide monohydrate attaches the alkyl group to the guanine base of DNA, shown to crosslink with DNA, causing strand breakage and inducing mutations .

Cyclophosphamide hydrate 动物研究

Dose Mice: 75 mg/kg[3] (p.o.), 250 mg/kg[4] (i.p., preferred dosage) Rat: 100 mg/kg - 222 mg/kg[5] (i.p.)
Administration p.o., i.p.

Cyclophosphamide hydrate 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03218852 IgA Nephropathy Phase 4 Active, not recruiting December 2021 China, Guangdong ... 展开 >> Guangdong General Hospital Guangzhou, Guangdong, China, 510080 收起 <<
NCT01670500 Breast Cancer Phase 2 Recruiting October 2021 United States, Colorado ... 展开 >> University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Virginia Borges, MD    303-724-0186    virginia.borges@ucdenver.edu    United States, Connecticut Smilow Cancer Hospital Care Center at Derby Recruiting Derby, Connecticut, United States, 06418 Contact: Erin Hofstatter, MD       erin.hofstatter@yale.edu    Smilow Cancer Hospital Care Center at Guilford Recruiting Guilford, Connecticut, United States, 06437 Contact: Erin Hofstatter, MD       erin.hofstatter@yale.edu    St. Francis Hospital and Medical Center Recruiting Hartford, Connecticut, United States, 06105 Contact: Erin Hofstatter, MD       erin.hofstatter@yale.edu    Yale School of Medicine Recruiting New Haven, Connecticut, United States, 06520 Contact: Erin Hofstatter, MD    203-737-1600    erin.hofstatter@yale.edu    United States, District of Columbia Georgetown University Medical Center Recruiting Washington, District of Columbia, United States, 20007 Contact: Claudine Isaacs, MD       isaacsc@georgetown.edu    Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016-2698 Contact: Antonio Wolff, MD       awolff@jhmi.edu    United States, Maryland Johns Hopkins Recruiting Baltimore, Maryland, United States, 21287 Contact: Antonio Wolff, MD       awolff@jhmi.edu    United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Steven Isakoff, MD, PhD    617-726-4920    sisakoff@partners.org    Principal Investigator: Steven Isakoff, MD, PhD          Dana-Farber Cancer Institute at Faulkner Hospital Withdrawn Boston, Massachusetts, United States, 02130 Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Nadine Tung, MD    617-667-7081    ntung@bidmc.harvard.edu    Principal Investigator: Nadine Tung, MD          Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Judy Garber, MD, MPH    617-632-2282    jegarber@partners.org    Principal Investigator: Judy Garber, MD, MPH          United States, New Hampshire New Hampshire Oncology-Hematology Withdrawn Hooksett, New Hampshire, United States, 03106 United States, New Jersey Rutgers Cancer Institute of New Jersey Active, not recruiting New Brunswick, New Jersey, United States, 08901 United States, New York Memorial Sloan-Kettering Cancer Center Withdrawn New York, New York, United States, 10065 United States, North Carolina Duke University Recruiting Durham, North Carolina, United States, 27708 Contact: P. Kelly Marcom       kelly.marcom@dm.duke.edu    United States, Rhode Island Women and Infants Hospital Recruiting Providence, Rhode Island, United States, 02905 Contact: Robert Legare, MD    401-453-7540    rlegare@wihri.org    United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Banu Arun, MD    713-792-2817    barun@mdanderson.org    MD Anderson in Katy Withdrawn Houston, Texas, United States, 77094 MD Anderson in the Bay Area Withdrawn Nassau Bay, Texas, United States, 77058 MD Anderson - Sugar Land Withdrawn Sugar Land, Texas, United States, 77478 MD Anderson - The Woodlands Withdrawn The Woodlands, Texas, United States, 77384 收起 <<
NCT00296205 Multiple Sclerosis Phase 2 Withdrawn(I am changing locati... 展开 >>ons to Johns Hopkins Medical Center) 收起 << February 2006 United States, New York ... 展开 >> Stony Brook University Hospital Stony Brook, New York, United States, 11794-8174 收起 <<

Cyclophosphamide hydrate 参考文献

[1]Schwartz PS, et al. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol. 2001 Dec;60(6):1268-1279.

[2]Liu P, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010 Jan;33(1):53-9.

[3]Harris RN, et al. Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokineticstudy. Cancer Chemother Pharmacol. 1984;12(3):167-72.

Cyclophosphamide hydrate 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.58mL

0.72mL

0.36mL

17.91mL

3.58mL

1.79mL

35.83mL

7.17mL

3.58mL

Cyclophosphamide hydrate 技术信息

CAS号6055-19-2
分子式C7H17Cl2N2O3P
分子量 279.101
别名 环磷酰胺水合物;环磷酰胺一水物;环磷酰胺，一水 ;Cyclophosphamide monohydrate;Cyclophosphamide (hydrate);NSC-26271 Monohydrate
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C
溶解度

DMSO: 40 mg/mL(143.32 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(179.15 mM)
动物实验配方

Tags: Cyclophosphamide hydrate | Cyclophosphamide monohydrate | 环磷酰胺水合物;环磷酰胺一水物;环磷酰胺，一水 | Inflammation Model | Nervous System Model | Other Modeling Agents | Anti-rheumatoid Arthritis | AmBeed-信号通路专用抑制剂 | Cyclophosphamide hydrate 纯度/质量文件 | Cyclophosphamide hydrate 生物活性 | Cyclophosphamide hydrate 动物研究 | Cyclophosphamide hydrate 临床数据 | Cyclophosphamide hydrate 参考文献 | Cyclophosphamide hydrate 实验方案 | Cyclophosphamide hydrate 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z